Introduction

When a joint is painful or stiff from cartilage wear, patients often face a choice between symptom management and something more regenerative — yet without wanting major surgery. The ChondroFiller injection sits in that space: a non-surgical, outpatient procedure that places a collagen scaffold directly into the joint to support the body's own repair process. This article explains what the procedure involves, what ChondroFiller is, and what patients can reasonably expect.

What ChondroFiller Is

ChondroFiller is a Class III CE-marked medical device manufactured by Meidrix Biomedicals in Germany. It is an acellular (cell-free) Type I collagen hydrogel scaffold, supplied in a dual-chamber syringe. When the two components are mixed during delivery they gel in situ — typically within three to five minutes — forming a stable, self-adherent matrix within the cartilage defect. Because the scaffold is cell-free, it draws the patient's own progenitor cells from the synovium and underlying bone marrow into the defect, where they may differentiate and synthesise new cartilage-like tissue as the collagen is gradually resorbed over approximately one to two years.

ChondroFiller is distinct from the Liquid Cartilage procedure offered at the London Cartilage Clinic. The Liquid Cartilage protocol is a keyhole surgical procedure — performed under anaesthetic in theatre — that delivers ChondroFiller plus biological adjuncts and, where indicated, the patient's own stem cells. The injection described in this article is non-surgical and does not involve those surgical steps.

What the Appointment Involves

The procedure is performed as a clinic visit, not a hospital admission. There is no general anaesthetic. Standard pre-procedure checks are carried out, and a local anaesthetic is applied to the skin and soft tissues around the joint to minimise discomfort. Ultrasound guidance is used throughout to direct the needle accurately to the target site. Precise placement matters: the dual-chamber syringe mixes the components at the needle tip as they are expressed, so gelation begins immediately on contact, and the solution must be delivered into the correct position before it sets. There are no incisions and no removal of tissue.

Recovery and After the Injection

Because no surgical incision is made, recovery is straightforward. A brief period of reduced loading is usually advised in the days after the procedure to allow the gel to stabilise, but a hospital stay is not required and most patients return to normal daily activities promptly. The biological process — cell recruitment, differentiation, and matrix synthesis — unfolds over weeks to months, so any symptomatic improvement should not be expected immediately. Benefits vary between patients and cannot be guaranteed. The injection is not a cure for osteoarthritis and does not reverse established joint degeneration; it is one tool within a joint-preservation strategy.

Conclusion

The ChondroFiller injection offers a non-surgical option for patients with accessible cartilage defects who prefer to avoid theatre and general anaesthesia. It works by placing a CE-marked collagen scaffold into the joint, where it gels in situ and supports the body's own cell-mediated repair. It is not a universal solution and is not equivalent to surgery for larger or more complex defects. For patients wondering whether it may be appropriate for their joint, a consultation at the London Cartilage Clinic is a sensible starting point for an honest assessment.

References

Corain, M., Zanotti, F., Giardini, M., Gasperotti, L., Invernizzi, E., Biasi, V., & Lavagnolo, U. (2023). The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis. Cartilage.